Sign in
Not yet recruitingPhase 2

HRS-3095 tablets for adults with chronic spontaneous urticaria

Tests HRS-3095 tablets against placebo in adults with chronic spontaneous urticaria.

Key facts

Who runs it
Chengdu Suncadia Medicine Co., Ltd.
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria
Status
Not yet recruiting
Phase
Phase 2
People taking part
190 people, planned
Started
Jul 2026
Expected to end
Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • HRS-3095 Tablet
  • HRS-3095 Tablet Placebo
Record updated
29 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic spontaneous urticaria (long-lasting hives with no known trigger). Their hives must not be well controlled by antihistamine tablets.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Chronic spontaneous urticaria for at least 6 months. Itching and wheals for ≥6 weeks despite regular second-generation H1-antihistamines. At randomization, UAS7 score ≥16 and HSS7 score ≥ 8.
Earlier treatment
People must be taking second-generation H1-antihistamines regularly. They must be on a stable dose of the specified antihistamine for at least 3 days before the first UAS score at screening.

Main reasons for not taking part

  • Other skin diseases that could affect the assessment, such as chronic inducible urticaria, urticarial vasculitis, atopic dermatitis or psoriasis
  • Bleeding or clotting problems, or use of blood thinners or antiplatelet drugs
  • Past or current liver disease
  • Past or current cancer, except some fully removed skin or cervical lesions
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Participants must be between 18 and 70 years of age, inclusive, at the time of signing the Informed Consent Form (ICF), with no restriction on gender
  • Participants must have a history of chronic spontaneous urticaria (CSU) with a disease duration of at least 6 months prior to screening
  • Participants must be diagnosed with H1-antihistamine-inadequately-controlled CSU at screening, defined as: having had persistent symptoms of pruritus and wheals for ≥6 weeks prior to screening, despite regular use of second-generation H1-antihistamines during that period
  • At randomization, the UAS7 score must be ≥16 (range: 0-42) and the HSS7 score ≥ 8 (range: 0-21)
  • Participants must have been on a stable dose of the specified second-generation H1-antihistamine for at least 3 days prior to the first UAS score at screening
  • Participants must be willing and able to complete logbook entries as required during the study and must have no missing daily UAS scores during the 7 days before randomization
  • Participants must voluntarily sign the Informed Consent Form (ICF) before any study-related procedures, be able to communicate effectively with the investigator, and be willing to strictly adhere to the requirements of the study protocol
  • Female participants of childbearing potential or male participants with a female partner of childbearing potential must agree to avoid donating sperm or ova and must agree to take highly effective contraceptive measures from the time of signing the ICF until 3 months after the last dose

Who cannot take part

  • Use of systemic or topical medications with therapeutic or immunomodulatory effects on the study disease during the relevant washout period prior to screening
  • Use of investigational drugs or medical devices within 8 weeks or 5 half-lives (if known), whichever is longer, or within 30 days (for small molecules) prior to screening
  • Vaccination or exposure to live or attenuated vaccines within 3 months prior to screening or participation in a vaccine-related clinical trial within 3 months prior to randomization
  • History of systemic antimicrobial use or presence of superficial skin infection (e.g., impetigo) within 4 weeks prior to screening
  • Major surgery performed within 3 months prior to randomization or planned during the study
  • Serious concomitant disease or any condition judged by the investigator to make the participant unsuitable for study participation
  • History of alcohol abuse within 6 months prior to screening (e.g., > 14 units/week) or history of illicit drug abuse within 6 months prior to screening
  • Any skin disease that could interfere with study assessment (e.g., chronic inducible urticaria, urticarial vasculitis, atopic dermatitis, psoriasis)
  • History or current coagulation-related risk (e.g., bleeding diathesis, coagulopathy, GI bleeding with clinical significance, antiplatelet or anticoagulant use, history of thrombosis or thromboembolic events, or increased risk of thrombosis)
  • History of liver disease or current treatment for liver disease (e.g., hepatitis, cirrhosis, liver failure)
  • History of malignancy or current malignancy (excluding completely resected and recurrence-free basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia)
  • Allergy to the study drug or any of its components
  • Any condition judged by the investigator that may affect the safety or efficacy evaluation of the study drug or participant compliance with the study procedures or diary
  • Abnormal findings in vital signs, physical examination, laboratory tests, ECG, chest X-ray/CT, or abdominal ultrasound during screening that have clinical significance and may affect study validity or participant safety
  • Pregnant or breastfeeding women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is being conducted to evaluate the efficacy, and safety of HRS-3095 with Chronic Spontaneous in adults, and to explore the reasonable dosage of HRS-3095 for Chronic Spontaneous Urticaria.

The 2 groups in the trial

  • HRS-3095 GroupTreatment being tested

    HRS-3095 in different doses.

    Treatment: HRS-3095 Tablet

  • HRS-3095 placebo GroupPlacebo, for comparison

    HRS-3095 blank preparation.

    Treatment: HRS-3095 Tablet Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of HRS-3095 in Patients With Chronic Spontaneous Urticaria
Plain-language title
HRS-3095 tablets for adults with chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07613866, who can take part
Record updated
29 May 2026